ArticleeLife2022
Multi-omics investigation of
Article in eLife, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 35 citations in OpenAlex.
- Ecological and dietary strategies to constrain Clostridioides difficile.Cell host & microbe · 2026Review
- The Gut Microbiome and Butyrate Differentiate Clostridioides difficile Colonization and Infection in Children.The Journal of infectious diseases · 2026Article
- Fluoroquinolone resistance without fluoroquinolone use; the genie is truly out of the bottle.Frontiers in microbiology · 2026Review
- Article
- Microbiome signatures ofmSphere · 2025Article
- Discovery of a Widespread Polyamine-Low-Molecular-Weight Thiol Hybrid Pathway inACS infectious diseases · 2025Article
- Phenotypic analysis of variousApplied and environmental microbiology · 2025Article
- Phenotypic analysis of variousbioRxiv : the preprint server for biology · 2025Article
- Commensal-pathogen dynamics structure disease outcomes during Clostridioides difficile colonization.Cell host & microbe · 2025Article
- Prioritizing isolation precautions: a patient-centered approach to infection prevention and control.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2025Review
- Review
- Understanding host immune responses iniMeta · 2024Review
- Genomic surveillance ofmBio · 2024Article
- Modeling the effects of prebiotic interventions on luminal and mucosa-associated gut microbiota without and withFrontiers in nutrition · 2024Article
- Gut Microbiota Associated withMicroorganisms · 2023Article
- One size does not fit all - Trehalose metabolism byMicrobial genomics · 2023Article
- Microbiome-Related and Infection Control Approaches to Primary and Secondary Prevention ofMicroorganisms · 2023Review
- CDBN-YGXZ, a Novel Small-Molecule Drug, Shows Efficacy against Clostridioides difficile Infection and Recurrence in Mouse and Hamster Infection Models.Antimicrobial agents and chemotherapy · 2023Article
- A Case of Successful Treatment of Recurrent Urinary Tract Infection by Extended-Spectrum β-Lactamase ProducingMicrobial drug resistance (Larchmont, N.Y.) · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.